A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Recruiting
The co-primary objectives of the study are to: Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/22/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
11/15/2023
Locations: Allcutis Research, Llc - Portsmouth, Portsmouth, New Hampshire
Conditions: Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
11/08/2023
Locations: Allcutis Research, Portsmouth, New Hampshire
Conditions: Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
10/30/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Atopic Dermatitis, Eczema
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
10/20/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Recruiting
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
Gender:
All
Ages:
12 years and above
Trial Updated:
10/18/2023
Locations: ALLCUTIS Research, Portsmouth, New Hampshire
Conditions: Atopic Dermatitis
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Recruiting
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/18/2023
Locations: ActivMed Practices & Research, Inc., Portsmouth, New Hampshire
Conditions: Atopic Dermatitis